CompletedNot applicableNCT04880083

Feeding Tolerance and Gut Maturation of Infants Consuming a Formula Rich in Glycoprotein

Studying Rapidly involuting congenital hemangioma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Société des Produits Nestlé (SPN)
Principal Investigator
Ying Wang
Shanghai Institute for Pediatric Research at Xinhua Hospital, Shanghai Jiao Tong University
Intervention
Commercially Available Starter Infant Formula(dietary_supplement)
Enrollment
120 target
Eligibility
All sexes
Timeline
20212022

Study locations (1)

Collaborators

Medrio, Inc · SAS Institute · Veeva Systems

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04880083 on ClinicalTrials.gov

Other trials for Rapidly involuting congenital hemangioma

Additional recruiting or active studies for the same condition.

See all trials for Rapidly involuting congenital hemangioma

← Back to all trials